Neurofilament light chain serum levels in E46K-SNCA mutation carriers
Objective: To demonstrate the usefulness of measuring the concentration of neurofilament light chain (NfL) in blood using Single Molecule Array matrix (SiMoA, Quanterix) as a…A novel likely pathogenic SNCA variant associated with Parkinson’s disease
Objective: To report a novel SNCA likely pathogenic variant. Background: The A53T mutation in the SNCA gene, encoding alpha-synuclein (a-syn), was the first established genetic…Alpha-synuclein preformed fibril (PFF)-triggered synucleinopathy recapitulates neurochemical features of human PD: A PET study in rats
Objective: To investigate longitudinal dopaminergic deficits and similarity to human Parkinson’s disease (PD) using PET imaging in the rat alpha-synuclein (a-syn) preformed fibril (PFF) model.…Quantifying movement to measure Parkinson’s Disease severity and progression in a Phase 2 Study (SPARK)
Objective: To develop and evaluate objective measures of Parkinson’s disease (PD) severity and progression by applying dynamical systems analysis to inertial sensor kinematic data. Background:…Variants in the saposin D domain of prosaposin gene are linked to Parkinson’s disease
Objective: To investigate whether the variants of prosaposin can be linked to Parkinson's disease (PD) [1]. Background: Recent growing investigations have promoted the evidence of…Predicting Longitudinal Atrophy in Parkinson’s Disease using SIR model
Objective: To predict longitudinal brain changes in Parkinson's disease (PD) using an agent-based model. Background: Considerable evidence suggests that α-synuclein(α-syn) behaves in a prion-like fashion,…Morphological changes of retina in patients with Parkinson’s disease and the role of α-synuclein in retinal damage
Objective: To analyze the characteristics of retinal structural changes in patients with PD by the noninvasive technology of OCT. Demonstrate the role of α-syn in pathological changes of…DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease
Objective: To analyze the CSF α-Synuclein and DJ1 Biomarkers correlating with SNCA and DJ1 gene polymorphisms and clinical parameters in PD. Background: Currently there is…Genetic Profiling of Early Synucleinopathy in Rat Nigrostriatal Dopamine Neurons
Objective: Identification of changes in gene expression in rat nigral neurons associated with early phases of synucleinopathy. Background: Early phases of synucleinopathies such as Parkinson’s…Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease
Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 51
- Next Page »